Form 4: InMed Director Andrew Hull Granted Stock Options

InMed Pharmaceuticals Inc. Director Andrew Hull was granted 1,750 employee stock options with an exercise price of $1.29.

Summary

• Andrew Hull, a Director of InMed Pharmaceuticals Inc. (INM), was granted 1,750 employee stock options.
• The options have an exercise price of $1.29 per share.
• The grant date for these options was December 19, 2025.
• The options will expire on December 18, 2030.
• Vesting for these options will occur 100% on the one-year anniversary of the grant date (December 18, 2026) or immediately prior to the next Annual General Meeting, whichever is sooner.
• Following this transaction, Mr. Hull beneficially owns 2,711 derivative securities (options).

Sentiment

Score: 6

Explanation: Slightly positive, as a director receiving options can signal confidence in the company's future, aligning their interests with shareholders. However, the transaction itself is routine and not indicative of significant operational news.

Positives

• The grant of stock options to a director can align management's interests with those of shareholders, incentivizing long-term performance.

Future Outlook

The options granted to Director Andrew Hull are scheduled to vest 100% on December 18, 2026, or immediately prior to the next Annual General Meeting, whichever occurs sooner, providing a future milestone for this equity compensation.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, often used to attract and retain talent, and to align the interests of directors with the long-term performance of the company.

Comparison to Industry Standards

• The grant of 1,750 options to a director is a relatively standard form of equity compensation within the industry, though the specific number and exercise price would need to be compared against peer companies like Canopy Growth (CGC), Tilray Brands (TLRY), or Cronos Group (CRON) to assess its relative size and value within typical compensation packages for similar roles and company stages.

Stakeholder Impact

• Shareholders: The grant of options to a director can be viewed positively as it aligns the director's financial interests with the company's long-term stock performance, potentially encouraging decisions that enhance shareholder value. However, it also represents potential future dilution if options are exercised.

Next Steps

• The options will vest 100% on December 18, 2026, or immediately prior to the next Annual General Meeting, whichever is sooner.

Key Dates

Keywords

InMed Pharmaceuticals, INM, Stock Options, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Grant